Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

for this reason. The overall rate of discontinuation due to adverse events was 16%(1).

About LBH589Because it is an investigational compound, the safety and efficacy profile of LBH589 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of uncertainty of clinical trials, there is no guarantee that LBH589 will ever be commercially available anywhere in the world.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "investigational," "potential," "investigating," "ongoing," "encouraging," "committed," "promising," or similar expressions, or by express or implied discussions regarding potential future approvals to market LBH589, or regarding potential future revenues from LBH589. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that LBH589 will be submitted or approved for sale in any market, or that LBH589 will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  Check-Cap Ltd. (NASDAQ: CHEK ), a ... of a preparation-free ingestible imaging capsule that utilizes low-dose ... its CEO, Guy Neev , will ring the ... Neev and Check-Cap will participate in the closing bell ... offering and simultaneous private placement which raised a total ...
(Date:3/30/2015)... 30, 2015  Building on the momentum of the first ... of medical alert systems, has announced aggressive plans to expand ... and Managed Care business models. The first quarter ... Tennessee and Louisiana ... contracts to span statewide coverage in each state. This brings ...
(Date:3/30/2015)... 2015 Research and Markets ... of the "Urological Catheters - Global ... offering. This report analyzes the ... Units and US$ Thousands by the following ... Peritoneal Catheters), and Urinary Catheters (Foley Catheters, ...
Breaking Medicine Technology:Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3MedScope's Aggressive 2015 Expansion Focuses on Medicaid Waiver and Managed Care Organizations 2Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 2Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 3Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 4Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 5Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 7
... N.J., Oct. 20 A meta-analysis of clinical data ... for the European Association for the Study of Diabetes ... (insulin detemir [rDNA origin] injection) was not associated with ... to human insulin(1,2). , The analysis conducted by ...
... Oct. 20 Digirad Corporation (Nasdaq: DRAD ) announced ... make an investor presentation at the BIOCOM 4th Annual Investor ... conference will be held at the Hyatt Regency La Jolla ... with slides will include a discussion of Digirad,s business, strategic ...
Cached Medicine Technology:Data Analysis Reinforces the Safety Profile of Levemir(R) 2Data Analysis Reinforces the Safety Profile of Levemir(R) 3Data Analysis Reinforces the Safety Profile of Levemir(R) 4
(Date:3/31/2015)... If you or someone you love is ... Irritable Bowel Syndrome (IBS), you will want to tune ... Television® at 7:30am EDT/PDT on either Wednesday, April 1st ... informative health segment featuring interviews with Board Certified Gastroenterologist ... and Medical Scientist Victoria Jaison, PhD. To learn more, ...
(Date:3/31/2015)... “ Prong ” was featured on NewsWatch as part ... coolest technology products available to consumers. Scott Steinberg, a technology ... shared with viewers how this phone case ensures that users ... when their phone is running out of power and they ... that is a solution to this problem. The PWR Case ...
(Date:3/31/2015)... 2015 A new study by Health eCareers ... rank employee turnover as their greatest staffing concern this year ... the battle – once you have them, you need to ... trends in healthcare recruiting blog series , which profiles ... Turnover in hospitals has high numbers and results in high ...
(Date:3/31/2015)... The Buffalo Bills athletic training staff ... for distinguished service to its club, community, and the ... Trainers’ Association (NYSATA) is proud to recognize such a ... - especially during March as part of National Athletic ... for NFL Athletic Training Staff of the Year ...
(Date:3/30/2015)... Fl (PRWEB) March 31, 2015 AlignLife ... Hamtaee has recently opened his AlignLife clinic. As part ... offering of chiropractic, rehabilitation and nutritional consulting for all ... AlignLife is based on the expertise and compassion of ... pass a rigorous evaluation process and an extensive training ...
Breaking Medicine News(10 mins):Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 2Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 3Health News:EnteraGam® to Be Featured on The Balancing Act® Airing on Lifetime Television® 4Health News:The Swiss Army Knife of Phone Cases was Featured on NewsWatch Television 2Health News:New Survey Finds Staff Turnover Top Concern for Healthcare Recruiters in 2015 2Health News:New Survey Finds Staff Turnover Top Concern for Healthcare Recruiters in 2015 3Health News:New Survey Finds Staff Turnover Top Concern for Healthcare Recruiters in 2015 4Health News:NYS Athletic Trainers' Association Congratulates Buffalo Bills Athletic Training Staff for National Award 2Health News:NYS Athletic Trainers' Association Congratulates Buffalo Bills Athletic Training Staff for National Award 3
... a Cesarean operation to deliver Japan's male heir. The ... doctor of the Imperial Household agency//. ,he ... the placenta, a condition called as placenta previa. "We ... operation. It is also highly possible that the delivery ...
... places and has put the draft regulation out for consultation//. ... government wanted to know about the people's views ahead of ... that it would be nice if the smoking ban extended ... that the plan would be expensive and is very complicated. ...
... chemicals and pharmaceutical companies have evinced interest to ... Chemicals Co already committing Rs 1,665 crore investment ... , Union Chemicals and Fertilisers Minister Ram Vilas ... led a delegation to Japan recently, said during ...
... human cancers involve mutations in the p53 tumor-suppressor gene, ... protein in defending// against cancer. Similarly, roughly 95 percent ... its DNA-binding core domain, pointing to this region of ... activity. ,Clearly, a detailed view of the ...
... dangers of sun exposure that are backed by research proving ... of developing skin// cancer, Americans are still getting sunburned. ... American Academy of Dermatology reported that 39 percent of respondents ... one sunburn in the previous 12 months, a 22 percent ...
... researchers, in collaboration with investigators at Johns Hopkins University, ... new vaccine against the West Nile virus. ... making its yearly appearance in Middle Tennessee. While no ... the state so far this season, mosquitoes collected from ...
Cached Medicine News:Health News:DNA-bound p53 Tumor Suppressor Protein Structure Determined 2Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 2Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 3Health News:University Participating in West Nile Vaccine Trial 2
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
... Interventions, like all important missions, ... guide you to your destination. ... you this dependability. So you ... the intervention and not have ...
Medicine Products: